These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31061148)

  • 21. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
    O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
    BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Lampri N; Galani I; Poulakou G; Katsarolis I; Petrikkos G; Giamarellou H; Souli M
    J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates.
    Al-Zarouni M; Senok A; Rashid F; Al-Jesmi SM; Panigrahi D
    Med Princ Pract; 2008; 17(1):32-6. PubMed ID: 18059098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].
    de Cueto M; Hernández JR; López-Cerero L; Morillo C; Pascual A
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):613-6. PubMed ID: 17194386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the effectiveness of three different cephalosporin/clavulanate combinations for the phenotypic confirmation of extended-spectrum beta-lactamase producing bacteria isolated from urine samples at National Public Health Laboratory, Kathmandu, Nepal.
    Bhandari R; Pant ND; Poudel A; Sharma M
    BMC Res Notes; 2016 Aug; 9():390. PubMed ID: 27488224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of temocillin against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains isolated from urinary tract infections in France.
    Duployez C; Loïez C; Cattoen C; Wallet F; Vachée A
    Med Mal Infect; 2019 Feb; 49(1):47-53. PubMed ID: 30396720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
    Raja NS
    J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
    Afridi FI; Farooqi BJ
    J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
    Melchers MJ; van Mil AC; Mouton JW
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing
    Abodakpi H; Chang KT; Gao S; Sánchez-Díaz AM; Cantón R; Tam VH
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended-Spectrum beta (β)-Lactamases and Antibiogram in Enterobacteriaceae from Clinical and Drinking Water Sources from Bahir Dar City, Ethiopia.
    Abera B; Kibret M; Mulu W
    PLoS One; 2016; 11(11):e0166519. PubMed ID: 27846254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide.
    Drieux L; Brossier F; Sougakoff W; Jarlier V
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():90-103. PubMed ID: 18154532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections.
    Fransen F; Melchers MJ; Meletiadis J; Mouton JW
    J Antimicrob Chemother; 2016 Oct; 71(10):2883-9. PubMed ID: 27278898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
    Tofteland S; Haldorsen B; Dahl KH; Simonsen GS; Steinbakk M; Walsh TR; Sundsfjord A;
    J Clin Microbiol; 2007 Jan; 45(1):199-205. PubMed ID: 17079502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum beta-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria.
    Stürenburg E; Lang M; Horstkotte MA; Laufs R; Mack D
    J Antimicrob Chemother; 2004 Nov; 54(5):870-5. PubMed ID: 15471997
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Monogue ML; Giovagnoli S; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Nguyen HM; Shier KL; Graber CJ
    J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula.
    Medeiros AA; Crellin J
    Pediatr Infect Dis J; 1997 Mar; 16(3 Suppl):S49-55. PubMed ID: 9076836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.